secwatch.observer — SEC 8-K summary
======================================

Issuer:     Monte Rosa Therapeutics, Inc. (GLUE)
CIK:        0001826457
Form:       8-K
Filed at:   2026-09-08T11:02:13+00:00
Accession:  0001193125-26-384360
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Monte Rosa earns $50M milestone as Novartis starts Phase 2 Sjögren's study of MRT-6160
--------------------------------------------------------------------------------

- Novartis initiated Phase 2a/b double-blind, placebo-controlled trial of VAV1 degrader MRT-6160 (DDY391) in Sjögren's disease; first patient visit triggers $50M payment to Monte Rosa.
- Study tests up to 52 weeks of treatment; identifier NCT07737743; dose selection for Phase 3.
- Monte Rosa eligible for up to $2.1B in development, regulatory, sales milestones from Novartis agreement.
- Phase 1 data showed >90% VAV1 degradation in T cells with no serious adverse effects; additional Phase 2 studies expected.
- Novartis funds Phase 2; Monte Rosa co-funds Phase 3 and shares 30% of U.S. profits/losses, plus ex-U.S. royalties.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1826457/000119312526384360/0001193125-26-384360-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1826457/000119312526384360/glue-20260908.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-384360

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer